Drug
Ervogastat clinical trials
Also written PF-06865571.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ervogastat is read from its arms, and is right about nine times in ten.
Testing it · 13
- Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)CompletedPhase 2PfizerNCT04321031Written as PF-06865571
- A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.CompletedPhase 1PfizerNCT04866225Written as Oral PF-06865571
- A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise HealthyCompletedPhase 1PfizerNCT04839393Written as PF-06882961 + PF-06865571
- Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic SteatohepatitisCompletedPhase 2PfizerNCT04399538Written as PF-06865571
- Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy SubjectsCompletedPhase 1PfizerNCT04091061Written as PF-06865571 100 mg
- A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.CompletedPhase 2PfizerNCT03776175Written as PF-06865571 Monotherapy
- 2-Week Study In People With Nonalcoholic Fatty Liver DiseaseCompletedPhase 1PfizerNCT03513588Written as PF-06865571
- Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult ParticipantsCompletedPhase 1PfizerNCT04044053Written as PF-06865571 400 mg Immediate Release (IR) in Fed State
- Drug-Drug Interaction Study to Evaluate the Effect of PF-06865571 on Metformin PharmacokineticsCompletedPhase 1PfizerNCT03593707Written as PF-06865571
- Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult SubjectsCompletedPhase 1PfizerNCT03534648Written as PF-06865571 administered Day 7-14
- A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult SubjectsCompletedPhase 1PfizerNCT03230383Written as PF-06865571
- A Study To Evaluate Different Formulations Of PF-06865571 In Healthy SubjectsCompletedPhase 1PfizerNCT03372044Written as PF-06865571 Immediate release suspension
- Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571CompletedPhase 1PfizerNCT03092232Written as PF-06865571
Codes
What other systems call ervogastat · ClinicalTrials.gg INT002012
- MeSH (NLM) C000726790ervogastatOne source NLM
- UNII (FDA) BSOIY5AKQWERVOGASTATConfirmed FDA, NLM, Wikidata
- Wikidata Q123530868ervogastatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C179085ErvogastatOne source FDA
- DrugBank DB21489One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000726790 | ervogastat | One source NLM |
| UNII (FDA) | BSOIY5AKQW | ERVOGASTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123530868 | ervogastat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C179085 | Ervogastat | One source FDA |
| DrugBank | DB21489 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.